Filtered By:
Specialty: Hematology
Source: Seminars in Thrombosis and Hemostasis
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 50 results found since Jan 2013.
Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment
Semin Thromb Hemost DOI: 10.1055/s-0043-1771270Ischemic stroke is an important cause of morbidity and mortality in cancer patients. The underlying mechanisms linking cancer and stroke are not completely understood. Long-standing and more recent evidence suggests that cancer-associated prothrombotic states, along with treatment-related vascular toxicity, such as with chemotherapy and immunotherapy, contribute to an increased risk of ischemic stroke in cancer patients. Novel biomarkers, including coagulation, platelet and endothelial markers, cell-free DNA, and extracellular vesicles are being investigated for their potentia...
Source: Seminars in Thrombosis and Hemostasis - July 28, 2023 Category: Hematology Authors: Costamagna, Gianluca Navi, Babak B. Beyeler, Morin Hottinger, Andreas F. Alberio, Lorenzo Michel, Patrik Tags: Review Article Source Type: research
Hematocrit and Stroke: A Forgotten and Neglected Link?
Semin Thromb Hemost DOI: 10.1055/s-0037-1602663Stroke is considered among the most common causes of mortality and disability, leading to dramatic socioeconomic consequences. From a pathophysiologic perspective, enhanced blood viscosity due to increased hematocrit might be associated with stroke through impaired cerebral blood perfusion. This association has remained rather neglected during previous decades, but newly emerged as an epicenter of scientific interest due to the unexpected elevation of stroke rates with sodium-glucose cotransporter-2 inhibitors, a new class of hypoglycemic drugs with otherwise dramatic cardiova...
Source: Seminars in Thrombosis and Hemostasis - June 13, 2017 Category: Hematology Authors: Stavropoulos, Konstantinos Imprialos, Konstantinos P. Bouloukou, Sofia Boutari, Chrysoula Doumas, Michael Tags: Review Article Source Type: research
Fibrinolysis and Remote Ischemic Conditioning: Mechanisms and Treatment Perspectives in Stroke
In conclusion, a single RIC treatment does not affect fibrinolysis in the acute phase, whereas long-term RIC administration may increase endogenous fibrinolysis. Increased endogenous fibrinolysis is unlikely to be the mediator of the acute neuroprotective effect of RIC in stroke patients, whereas it may partly explain the reduced stroke recurrence associated with long-term RIC treatment. [...] Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USAArticle in Thieme eJournals: Table of contents | Abstract | Full text
Source: Seminars in Thrombosis and Hemostasis - April 20, 2021 Category: Hematology Authors: Krag, Andreas Engel Blauenfeldt, Rolf Ankerlund Tags: Review Article Source Type: research
Applications of Nanotechnology in the Diagnosis and Therapy of Stroke
Semin Thromb Hemost DOI: 10.1055/s-0039-3399568Stroke is a leading cause of death and disability worldwide. The classification of stroke subtypes is difficult but critical for the prediction of clinical course and patient management, and limited treatment options are available. There is an urgent need for improvements in both diagnosis and therapy. Strokes have rapidly evolving phases of damage involving unique compartments of the brain, which imposes severe limitations for current diagnostic and treatment procedures. The rapid development of nanotechnology in other areas of modern medicine has ignited a widespread interes...
Source: Seminars in Thrombosis and Hemostasis - December 12, 2019 Category: Hematology Authors: Landowski, Lila M. Niego, Be'eri Sutherland, Brad A. Hagemeyer, Christoph E. Howells, David W. Tags: Review Article Source Type: research
α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke
Semin Thromb HemostDOI: 10.1055/s-0036-1585077Thrombotic vascular occlusion is the leading cause of ischemic stroke. High blood levels of α2-antiplasmin (a2AP), an ultrafast, covalent inhibitor of plasmin, have been linked in humans to increased risk of ischemic stroke and failure of tissue plasminogen activator (tPA) therapy. Consistent with these observations, a2AP neutralizes the therapeutic benefit of tPA therapy in experimental stroke. In addition, a2AP has deleterious, dose-related effects on ischemic brain injury in the absence of therapy. Experimental therapeutic inactivation of a2AP markedly reduces microvascular...
Source: Seminars in Thrombosis and Hemostasis - July 28, 2016 Category: Hematology Authors: Reed, Guy L. Houng, Aiilyan K. Singh, Satish Wang, Dong Tags: Review Article Source Type: research
Endovascular Stroke Therapy
Semin Thromb Hemost DOI: 10.1055/s-0037-1603984Acute ischemic stroke therapy has rapidly evolved over the past two decades. Recently, a paradigm shift has occurred in the treatment of acute ischemic stroke due to large vessel occlusion with the publication of several randomized trials proving that mechanical thrombectomy with stent retriever devices improves clinical outcome in comparison to intravenous thrombolysis. Furthermore, pooled data from the clinical trials suggest that mechanical thrombectomy can improve outcome in a broad range of patients, and that the sooner the intervention can be performed, the greater the b...
Source: Seminars in Thrombosis and Hemostasis - July 27, 2017 Category: Hematology Authors: Caganap, Scott D. Smith, Wade S. Tags: Review Article Source Type: research
Red Blood Cell Distribution Width Is an Independent Predictor of Outcome in Patients Undergoing Thrombolysis for Ischemic Stroke
Semin Thromb Hemost DOI: 10.1055/s-0036-1592165An appropriate and timely management, including early diagnosis and accurate prognostication, is the mainstay for managed care of patients with acute ischemic stroke. Since red blood cell distribution width (RDW) was found to be an independent predictor of clinical outcomes in patients with thrombotic disorders, we designed a retrospective observational study to investigate whether the RDW value may also retain predictive significance in stoke patients undergoing thrombolytic therapy. This retrospective study was based on all patients admitted to the Emergency Department (ED) ...
Source: Seminars in Thrombosis and Hemostasis - November 2, 2016 Category: Hematology Authors: Turcato, Gianni Cappellari, Manuel Follador, Luca Dilda, Alice Bonora, Antonio Zannoni, Massimo Bovo, Chiara Ricci, Giorgio Bovi, Paolo Lippi, Giuseppe Tags: Review Article Source Type: research
Thrombolysis and Thrombectomy for Acute Ischemic Stroke: Strengths and Synergies
Semin Thromb HemostDOI: 10.1055/s-0036-1585078Acute ischemic stroke is responsible for around 80% of all strokes and is a leading cause of disability and death globally. There are two potential treatment strategies: restoring blood flow (reperfusion) and preventing cellular injury (neuroprotection). As yet, all the successful trials have involved reperfusion with numerous failures of neuroprotectants. There are two proven reperfusion strategies. Intravenous thrombolysis with alteplase was first demonstrated to reduce disability with publication of the National Institute of Neurological Disorders and Stroke tissue plasminog...
Source: Seminars in Thrombosis and Hemostasis - July 28, 2016 Category: Hematology Authors: Campbell, Bruce C. V. Tags: Review Article Source Type: research
The Applicability of Thromboelastography in Acute Ischemic Stroke: A Literature Review
This article aims to highlight the potential use of TEG in AIS patients by reviewing available studies. We conducted a literature review, including PubMed and Cochrane library databases. The following keywords were used to find relevant studies: thromboelastography, TEG, acute ischemic stroke, stroke, coagulopathy, antiplatelet, and anticoagulant treatment. We identified 142 papers and after abstract review, we included 24 studies in this report. TEG identified a hypercoagulable state in AIS patients represented by short R, K, and greater α angle in all papers included. Modification of TEG parameters induced by intravenou...
Source: Seminars in Thrombosis and Hemostasis - September 2, 2022 Category: Hematology Authors: P îrlog, Bianca O. Grotta, James C. Tags: Review Article Source Type: research
Risk Stratification Models in Atrial Fibrillation
Semin Thromb Hemost DOI: 10.1055/s-0036-1597285Atrial fibrillation (AF) is associated with an increased risk of stroke compared with the general population. AF-related stroke confers a higher mortality and morbidity risk, and thus, early detection and assessment for the initiation of effective stroke prevention with oral anticoagulation are crucial. Simple and practical risk assessment tools are essential to facilitate stroke and bleeding risk assessment in busy clinics and wards to aid decision making. At present, the CHA2DS2VASc score is recommended by guidelines as the most simple and practical method of assessing strok...
Source: Seminars in Thrombosis and Hemostasis - January 26, 2017 Category: Hematology Authors: Shahid, Farhan Lip, Gregory Y. H. Tags: Review Article Source Type: research
New-Onset Atrial Fibrillation in Sepsis: A Narrative Review
Semin Thromb Hemost DOI: 10.1055/s-0040-1714400Atrial fibrillation (AF) is a frequently identified arrhythmia during the course of sepsis. The aim of this narrative review is to assess the characteristics of patients with new-onset AF related to sepsis and the risk of stroke and death, to understand if there is a need for anticoagulation. We searched for studies on AF and sepsis on PubMed, the Cochrane database, and Web of Science, and 17 studies were included. The mean incidence of new-onset AF in patients with sepsis was 20.6% (14.7% in retrospective studies and 31.6% in prospective). Risk factors for new-onset AF includ...
Source: Seminars in Thrombosis and Hemostasis - September 22, 2020 Category: Hematology Authors: Aibar, Jesus Schulman, Sam Tags: Review Article Source Type: research
Comparative Efficacy and Safety of the Non–Vitamin K Antagonist Oral Anticoagulants for Patients with Nonvalvular Atrial Fibrillation
Semin Thromb HemostDOI: 10.1055/s-0035-1544156The non–vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor (dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have been shown to be at least as efficacious and safe as conventional oral anticoagulants, such as the vitamin K antagonists (VKAs) (e.g., warfarin), for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Each NOAC has various advantages and specific features, and therefore decisions regarding appropriate stroke prevention require individual assessment of stroke and bleeding ri...
Source: Seminars in Thrombosis and Hemostasis - February 15, 2015 Category: Hematology Authors: Senoo, KeitaroLip, Gregory Y. H. Source Type: research
Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience
Semin Thromb Hemost DOI: 10.1055/s-0037-1615261This is an observational study to investigate the efficacy and safety of nonvitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with bioprosthetic valves or prior surgical valve repair in clinical practice. A total of 122 patients (mean age: 74.1 ± 13.2; 54 females) with bioprosthetic heart valve or surgical valve repair and AF treated with NOACs were included in the analysis. The mean CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >75 years, Diabetes mellitus, prior Stroke or transient ischemic attack, Vascular disease) and...
Source: Seminars in Thrombosis and Hemostasis - January 5, 2018 Category: Hematology Authors: Russo, Vincenzo Attena, Emilio Mazzone, Carmine Esposito, Francesca Parisi, Valentina Bancone, Ciro Rago, Anna Nigro, Gerardo Sangiuolo, Raffaele D' Onofrio, Antonio Tags: Original Article Source Type: research
Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials
Semin Thromb Hemost DOI: 10.1055/s-0040-1716874Thrombotic cardiovascular disease (myocardial infarction [MI], stroke, and venous thromboembolism [VTE]) remains a major cause of death and disability. Sulodexide is an oral glycosaminoglycan containing heparan sulfate and dermatan sulfate. We conducted a systematic review and meta-analysis to determine the cardiovascular efficacy, and safety of sulodexide versus control in randomized controlled trials (RCTs). We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for RCTs reporting cardiovascular outcomes in patients receiving sulodexide versus co...
Source: Seminars in Thrombosis and Hemostasis - October 21, 2020 Category: Hematology Authors: Bikdeli, Behnood Chatterjee, Saurav Kirtane, Ajay J. Parikh, Sahil A. Andreozzi, Giuseppe M. Desai, Nihar R. Francese, Dominic P. Gibson, C Michael Piazza, Gregory Goldhaber, Samuel Z. Eikelboom, John W. Krumholz, Harlan M. Stone, Gregg W. Tags: Review Article Source Type: research
